PRISM: Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) (clinicaltrials.gov) - Dec 16, 2025 - P1/2 | N=21 | Not yet recruiting | Sponsor: Zhongmou Therapeutics
New P1/2 trial • Gene Therapies • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa
|